Hyloris Developments SA

11/08/2026 | Press release | Distributed by Public on 11/08/2026 12:20

Alenura Delivers Positive Phase 2 Results in Interstitial Cystitis/Bladder Pain Syndrome Trial

08 Nov 2026 19:04 CET

Subscribe

Issuer

HYLORIS PHARMACEUTICALS SA

Source

HYLORIS

Provider

Euronext

Company Name

HYLORIS

ISIN

BE0974363955

Symbol

HYL

Market

Euronext

Company press releases subscription

×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account.
Cancel
Hyloris Developments SA published this content on November 08, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 08, 2026 at 18:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]